Background: Several common metabolic risk factors contribute to development of both non-alcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD). The aim was to determine prevalence of NAFLD in patients with CAD.
Methods: This prospective study was carried out from December 2011 to June 2012. All patients with documented diagnosis of CAD with stenosis of one of the main coronary arteries or their branches were included in the study. Ultrasound examination of liver was performed in all patients to diagnose hepatic steatosis. Accordingly, the severity of steatosis was graded from 0 (absence of steatosis) to 3 (severe steatosis). Finally, prevalence of NAFLD was determined in the studied patients.
Results: Among 170 patients with CAD included in the study, 63 and 17 had grade 1 and 2 hepatic steatosis in ultrasound examination, respectively, providing prevalence of 47% in studied population. There was no significant difference between patients with NAFLD and those without NAFLD regarding gender (P = 0.120), presence of diabetes mellitus (P = 0.270), hyperlipidemia (P = 0.210) and hypertension (P = 0.870). There was no association between involvement of left anterior descending artery and hepatic steatosis (P = 0.870).
Conclusion: The present study indicated a high prevalence of NAFLD in patients with documented CAD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266138 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of Transaminitis and Metabolic Dysfunction-Associated Steatotic Liver Disease Among Young Indian Adults-A Population-Based Study.
J Clin Exp Hepatol
November 2024
Health Services Department, Govt of Kerala, Thiruvananthapuram, India.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) with onset in youth may be more consequential for adverse outcomes than that detected later in adulthood. Transaminitis in the general population is a marker of the prevalence of MASLD. There are no previous community-based studies in Indian youth assessing the prevalence of transaminitis.
View Article and Find Full Text PDFMAFLD: Exploring the Systemic Effects Beyond Liver.
J Community Hosp Intern Med Perspect
January 2025
Division of Hospital Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing global health concern which is driven by the increasing prevalence of diabetes and obesity. MAFLD is characterized by excessive fat accumulation in the liver, which encompasses a range of conditions, from simple hepatic steatosis to more severe forms. This condition is associated with various complications, including chronic kidney disease (CKD), Cardiovascular Disease (CVD), liver cirrhosis, and even malignancy.
View Article and Find Full Text PDFPrecision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD.
Liver Int
February 2025
Department of Epidemiology and Data Science, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
Background And Aims: The performance of non-invasive liver tests (NITs) is known to vary across settings and subgroups. We systematically evaluated whether the performance of three NITs in detecting advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) varies with age, sex, body mass index (BMI), type 2 diabetes mellitus (T2DM) status or liver enzymes.
Methods: Data from 586 adult LITMUS Metacohort participants with histologically characterised MASLD were included.
Associations of the Intake of Individual and Multiple Flavonoids with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States.
Nutrients
January 2025
Department of Nutrition, School of Public Health, Sun Yat-sen University, 74 Zhong Shan Road 2, Guangzhou 510080, China.
Background: Evidence regarding the individual and combined impact of dietary flavonoids on the risk of metabolic dysfunction associated with steatotic liver disease (MASLD) remains scarce. Our objective is to evaluate the association between individual and multiple dietary flavonoids with MASLD in adults.
Methods: Data sets were obtained from the National Health and Nutrition Examination Survey (NHANES), 2017-2018.
The Counteracting Effect of Chrysin on Dietary Fructose-Induced Metabolic-Associated Fatty Liver Disease (MAFLD) in Rats with a Focus on Glucose and Lipid Metabolism.
Molecules
January 2025
Unit of Biochemistry, Department of Biomedicine, Faculty of Medicine of Porto, University of Porto, 4200-319 Porto, Portugal.
The prevalence of metabolic syndrome has been exponentially increasing in recent decades. Thus, there is an increasing need for affordable and natural interventions for this disorder. We explored the effect of chrysin, a dietary polyphenol, on hepatic lipid and glycogen accumulation, metabolic dysfunction-associated fatty liver disease (MAFLD) activity score and oxidative stress and on hepatic and adipose tissue metabolism in rats presenting metabolic syndrome-associated conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!